drugset / Trial / NCT04449536
Cysteine-lowering Treatment With Mesna
Phase 1
Completed
25 enrolled
University of Oslo
Oslo University Hospital · collabUniversity of Oxford · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the efficacy of the drug Mesna® (Uromitexan) in healthy participants with overweight or obesity with respect to change in plasma concentrations of total cysteine, following single ascending doses of oral Mesna.
Timeline
- Start
- 2020-11-02
- Primary completion
- 2021-10-21
- Completion
- 2021-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 400 mg | Oral |
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 800 mg | Oral |
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 1200 mg | Oral |
| Subject | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 1600 mg | Oral |